KR102055890B1 - Novel Bacillus amyloliquefaciens and Use thereof - Google Patents
Novel Bacillus amyloliquefaciens and Use thereof Download PDFInfo
- Publication number
- KR102055890B1 KR102055890B1 KR1020180089530A KR20180089530A KR102055890B1 KR 102055890 B1 KR102055890 B1 KR 102055890B1 KR 1020180089530 A KR1020180089530 A KR 1020180089530A KR 20180089530 A KR20180089530 A KR 20180089530A KR 102055890 B1 KR102055890 B1 KR 102055890B1
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- present
- bacillus amyloliquefaciens
- skin
- rpg
- Prior art date
Links
- 241000193744 Bacillus amyloliquefaciens Species 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 239000002537 cosmetic Substances 0.000 claims abstract description 25
- 239000006166 lysate Substances 0.000 claims abstract description 16
- 235000013376 functional food Nutrition 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 10
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 25
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 25
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 abstract description 21
- 230000009759 skin aging Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 14
- 230000037303 wrinkles Effects 0.000 abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 13
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 11
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 230000002757 inflammatory effect Effects 0.000 abstract description 8
- 210000004927 skin cell Anatomy 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 230000001603 reducing effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000006872 improvement Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- -1 pack Substances 0.000 description 11
- 230000003712 anti-aging effect Effects 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 230000001153 anti-wrinkle effect Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 239000000344 soap Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 5
- 108060005980 Collagenase Proteins 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- IRHVLQMEQPABHG-ZLYSWTFPSA-N (3r,4r,5r,6r,7r,8r,9s,10r,13r,14r,17r)-3,4,6,7-tetrahydroxy-17-[(1s)-1-[(2s,4s)-6-hydroxy-4-propan-2-yloxan-2-yl]ethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,16,17-tetradecahydrocyclopenta[a]phenanthren-15-one Chemical compound C1[C@H](C(C)C)CC(O)O[C@@H]1[C@@H](C)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](O)[C@H](O)[C@@H]4[C@@H](O)[C@H](O)[C@H]3[C@H]2C(=O)C1 IRHVLQMEQPABHG-ZLYSWTFPSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical class O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DCPWYLSPIAHJFU-YKRRISCLSA-N (2s,3s,4s)-4-amino-2,3-dihydroxy-n-[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydroisochromen-3-yl]-3-methylbutyl]hexanediamide Chemical compound C1=CC(O)=C2C(=O)O[C@H]([C@@H](NC(=O)[C@@H](O)[C@@H](O)[C@@H](N)CC(N)=O)CC(C)C)CC2=C1 DCPWYLSPIAHJFU-YKRRISCLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PFKYCGAUNWCWNO-UHFFFAOYSA-N 1,5-diphenyl-1h-tetrazol-1-ium;bromide Chemical compound [Br-].C1=CC=CC=C1[NH+]1C(C=2C=CC=CC=2)=NN=N1 PFKYCGAUNWCWNO-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- DCPWYLSPIAHJFU-UHFFFAOYSA-N Amicoumacin A Natural products C1=CC(O)=C2C(=O)OC(C(NC(=O)C(O)C(O)C(N)CC(N)=O)CC(C)C)CC2=C1 DCPWYLSPIAHJFU-UHFFFAOYSA-N 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001328122 Bacillus clausii Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 230000009604 anaerobic growth Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108010011532 polyfermenticin SCD Proteins 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- C12R1/07—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 새롭게 분리된 신규한 바실러스 아미로리퀘파시엔스 균주 및 이의 용도에 대한 것으로, 보다 상세하게는 피부보호, 주름개선 및 항염증 효능을 갖는 신규한 호기성 또는 통성 혐기성의 그람 양성균 균주 및 이를 이용한 화장료 조성물, 약학조성물 및 건강기능식품에 대한 것이다. The present invention relates to a newly isolated novel Bacillus amiriquefaciens strain and its use, and more particularly to a novel aerobic or permeable anaerobic Gram-positive bacteria strain having skin protection, wrinkle improvement and anti-inflammatory efficacy and Cosmetic compositions, pharmaceutical compositions and dietary supplements.
생균제(Probiotics)는 숙주의 장내 미생물 균형을 유지시킴으로써 유익한 작용을 하는 미생물을 총괄하며, 인체 의약품인 정장제나 유산균 제제, 사료첨가제 및 건강식품 등으로 사용되고 있다. 일반적으로 생균제로 사용되는 미생물들은 안전하며, 섭취시 생체 내 저해환경 즉 위장의 위산, 담낭의 담즙 및 소장에서 분비되는 각종 소화 효소에 저항력을 갖고, 대장과 직장에 도달해 증식하고 정착하는 능력을 갖는다[FAO/WHO, 2002; Homma 1998].Probiotics oversee the microorganisms that have beneficial effects by maintaining the balance of the host's intestinal microflora, and are used as formal medicines, lactobacillus preparations, feed additives, and health foods. In general, the microorganisms used as probiotics are safe, resistant to in vivo inhibitory environments such as gastric acid in the stomach, bile and small intestine of the gallbladder, and the ability to reach and colonize the large intestine and rectum. Have [FAO / WHO, 2002; Homma 1998].
생균제로 많이 이용되고 있는 세균은 Lactobacillus속, Streptococcus속, Bifidobacterium속 그리고 유포자 유산균인 Bacillus속 등이 있다. Bacteria that are widely used as probiotics include Lactobacillus genus, Streptococcus genus, Bifidobacterium genus and Bacillus genus of diffuser lactic acid bacteria.
바실러스(Bacillus) 속은 중요한 효소인 프로테아제, 아밀라제, 글루칸아제 및 셀룰라아제를 생성하며, 폴리펩타이드형의 바시트라신과 같은 항균 활성물질을 생성하며, 식중독균 외에도 위암의 원인인 헬리코박터 파이롤리(Helicobacter pylori)균에 대한 항균력을 가짐으로써, 생균제로 적합한 특성을 갖는다[Pinchuk et al., 2001; Tagg et al., 1995.]. 이미 1958년 이탈리아에서 일반 의약품으로서 B. clausii를 성분으로 한 Enterogermina의 상품화를 시작으로 바실러스 속을 이용한 생균제는 최소 50년 동안 사용되어 왔다. 또한, 미국의 nature's first Food, 일본의 bispan 및 중국의 medilac-vita 등 여러 나라에서 프로바이오틱 상품이 시판되고 있다. 생균제 정장제 중 바실러스 서브틸리스 2335 및 바실러스 리케니포르미스(B.licheniformis) 2336의 혼합 제제인 바이오스포린(Biosporin)의 바실러스 서브틸리스 2335가 위암의 원인인 헬리코박터 파이롤리균을 저해하는 항균물질인 Amicoumacin A를 분비한다는 연구결과가 있으며, 일본에서 분리된 Bispan 제품의 Bacillus poyfermenticus SCD는 polyfermenticin SCD라고 명명된 박테리오신을 생성한다고 보고 되었다[Cutting, 2010; Jun et al., 2007;]. 이렇듯 식품 유래 생균제는 다양한 기능을 가지면서 안전한 것으로 간주되고 있다. The genus Bacillus produces important enzymes such as proteases, amylases, glucanases and cellulase, and produces antimicrobial actives such as polypeptide-type bacitracin, and in addition to food poisoning bacteria, the bacterium Helicobacter pylori, a cause of stomach cancer. Having antimicrobial activity, it has suitable properties as a probiotic [Pinchuk et al., 2001; Tagg et al., 1995.]. As early as 1958, commercialization of Enterogermina containing B. clausii as a generic drug in Italy has been used for probiotics using the Bacillus genus for at least 50 years. Probiotic products are also available in many countries, including nature's first food in the United States, bispan in Japan, and medilac-vita in China. Among the probiotics, Bacillus subtilis 2335 from Biosporin, a mixed formulation of Bacillus subtilis 2335 and B.licheniformis 2336, is an antimicrobial agent that inhibits the bacterium Helicobacter pylori, which causes gastric cancer. There has been research showing that Amicoumacin A is secreted. It has been reported that Bacillus poyfermenticus SCD of Bispan product isolated in Japan produces bacteriocin named polyfermenticin SCD [Cutting, 2010; Jun et al., 2007;]. As such, food-derived probiotics have various functions and are considered safe.
이러한 바실러스 속 균주의 새로운 용도를 제공하고자 하는 시도들이 보고되고 있으며, 바실러스 아밀로리퀘파시엔스를 이용하여 면역기능, 항진균 효과. 등에 효능을 높이고자 한 시도는 있으나 피부노화 억제 등의 효과는 보고된 바 없다. Attempts have been made to provide new uses of these strains of Bacillus, and immune function, antifungal effects using Bacillus amyloliquefaciens. Attempts have been made to increase efficacy in the back, but the effects of inhibiting skin aging have not been reported.
한편, 기능성 화장품 소재 개발은 크게, 피부노화를 억제하는 항노화 소재 개발과 표피층의 멜라닌 형성 세포의 멜라닌 생합성을 저해하거나 생성된 멜라닌이 표피세포로 전달되는 경로를 차단하는 미백 소재 개발이 주류를 이루고 있고, 피부 염증을 억제하는 항염증 소재는 항노화 소재 범주에 드는 소재로서 기능성 화장품 소재 개발의 주요 탐색 수단으로 사용되고 있다.On the other hand, the development of functional cosmetic materials is mainly the development of anti-aging materials that inhibit skin aging and the development of whitening materials that inhibit melanin biosynthesis of melanin-forming cells of the epidermal layer or block the route of the generated melanin to the epidermal cells. In addition, the anti-inflammatory material for inhibiting skin inflammation is used as a major exploration means for the development of functional cosmetic materials as a material in the anti-aging material category.
이에 외부로부터 받는 과도한 물리적, 화학적 자극 및 스트레스, 영양결핍 등은 피부의 정상기능을 저하시키고 탄력손실, 각질화, 주름생성 등의 피부 노화현상을 촉진시키게 되는데, 이러한 현상을 방지하고 보다 건강하고 탄력있는 피부를 유지하기 위하여 종래 각종 동물, 식물, 미생물 등으로부터 얻은 생리활성물질들이 강화된 화장품을 사용함으로써 피부의 고유기능을 유지시키고 피부세포를 활성화시켜 피부노화를 효과적으로 억제하고 주름을 재선시키기 위한 노력이 있어 왔다. 그러나 이러한 기존의 화장품 원료들은 대부분 그 효능이 미진하거나 피부 부작용을 유발하는 등 여러 가지 문제점을 가지고 있었다.Therefore, excessive physical and chemical stimuli, stress, and nutritional deficiency received from the outside lower the normal function of the skin and promote skin aging phenomenon such as loss of elasticity, keratinization, and wrinkle formation. In order to maintain skin, efforts to maintain skin's inherent function and activate skin cells effectively inhibit skin aging and re-wrinkle wrinkles by using cosmetics reinforced with bioactive substances obtained from various animals, plants and microorganisms. It has been. However, most of these conventional cosmetic raw materials had various problems, such as insufficient efficacy or cause skin side effects.
이에 본 발명자들은 기존 항노화제나 항염증제의 부작용을 최소화하고, 노화 방지 효과 및 항염증 효과가 우수한 천연물 유래 조성물을 개발하고자 예의 노력한 결과, 신규 분리된 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) 균주가 피부 노화 방지 및 주름 개선, 그리고 염증 치료 및 개선에 있어 뛰어난 효과를 가진다는 것을 확인하고, 본 발명을 완성하였다.Accordingly, the present inventors have made efforts to minimize the side effects of existing anti-aging agents and anti-inflammatory agents, and to develop a natural-derived composition having excellent anti-aging and anti-inflammatory effects, and as a result, a newly isolated Bacillus amyloliquefaciens strain is used as a skin. The present invention has been completed, confirming that it has excellent effects in anti-aging and wrinkle improvement, and in treating and improving inflammation.
본 배경기술 부분에 기재된 상기 정보는 오직 본 발명의 배경에 대한 이해를 향상시키기 위한 것이며, 이에 본 발명이 속하는 기술분야에서 통상의 지식을 가지는 자에게 있어 이미 알려진 선행기술을 형성하는 정보를 포함하지 않을 수 있다. The above information described in this Background section is only for improving the understanding of the background of the present invention, and therefore does not include information forming prior art that is known to those of ordinary skill in the art. You may not.
본 발명의 목적은 피부보호, 주름개선 및 항염증 효능을 갖는 신규한 유산균 균주 및 이를 이용한 화장료 조성물, 약학조성물 및 건강기능식품을 제공하는데 있다. An object of the present invention is to provide a novel lactic acid bacteria strain having skin protection, wrinkle improvement and anti-inflammatory effect, and a cosmetic composition, pharmaceutical composition and health functional food using the same.
상기 목적을 달성하기 위하여, 본 발명은 신규한 바실러스 아밀로리퀘파시엔스 균주 및 이의 용도를 제공한다. In order to achieve the above object, the present invention provides a novel Bacillus amyloliquefaciens strain and its use.
구체적으로, 본 발명은 서열번호 1의 16S rRNA 서열을 가지는 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens RPG-B0001) 균주를 제공한다. Specifically, the present invention provides a Bacillus amyloliquefaciens RPG-B0001 strain having a 16S rRNA sequence of SEQ ID NO: 1.
본 발명은 또한, 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens RPG-B0001) (기탁번호 : KCCM12191P ) 균주를 제공한다. The present invention also provides Bacillus amyloliquefaciens RPG-B0001 (Accession No .: KCCM12191P) strain.
본 발명은 또한, 상기 균주, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 포함하는 피부 노화 방지 또는 주름 개선용 화장료 조성물을 제공한다. The present invention also provides a cosmetic composition for preventing skin aging or improving wrinkles, including any one or more of the above strains, lysates and cultures thereof.
본 발명은 또한, 상기 균주, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 포함하는 피부 노화 방지 또는 주름 억제용 약학 조성물을 제공한다. The present invention also provides a pharmaceutical composition for preventing skin aging or anti-wrinkle, comprising any one or more of the above strains, lysates and cultures thereof.
본 발명은 또한, 균주, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 포함하는 피부 노화 방지 또는 주름 개선용 건강기능식품을 제공한다.The present invention also provides a health functional food for preventing skin aging or improving wrinkles, including any one or more of strains, lysates and cultures thereof.
본 발명은 또한, 상기 균주, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 포함하는 염증의 예방 또는 치료용 약학 조성물을 제공한다. The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammation, including any one or more of the above strains, lysates and cultures thereof.
본 발명은 또한, 상기 균주, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 포함하는 염증의 예방 또는 개선용 건강기능식품을 제공한다. The present invention also provides a health functional food for the prevention or improvement of inflammation, including any one or more of the above strains, their lysates and their cultures.
본 발명은 피부보호, 주름개선 및 항염증 효능을 갖는 신규한 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens RPG-B0001) 균주 및 이를 이용한 화장료 조성물, 약학조성물 및 건강기능식품을 제공한다. The present invention provides a novel Bacillus amyloliquefaciens RPG-B0001 strain having a skin protection, wrinkle improvement and anti-inflammatory effect, and a cosmetic composition, a pharmaceutical composition, and a health functional food using the same.
본 발명에 따른 균주, 그 파쇄물 및 그 배양물은 기존 주름 개선제나 염증 치료제의 부작용을 최소화하여 피부에 안전하면서도, 피부노화의 주요 원인인 자외선 노출에 대하여 피부세포를 보호하는 작용을 나타내며, 피부 주름을 유발하는 효소를 효과적으로 감소 또는 억제할 수 있으므로, 피부 노화 방지 및 주름 개선에 유용하다. 아울러, 효과적으로 염증 매개 인자 발현을 억제하는 항염증 활성을 보이는바 염증 치료 및 개선에 있어 또한 유용하다. The strain according to the present invention, its lysate and its culture are safe for the skin by minimizing the side effects of the existing anti-wrinkle agent or inflammatory treatment agent, while also exhibiting the action of protecting skin cells against UV exposure, which is a major cause of skin aging, and skin wrinkles. Since it can effectively reduce or inhibit the enzyme causing the, it is useful for preventing skin aging and wrinkle improvement. In addition, it exhibits anti-inflammatory activity that effectively inhibits expression of inflammatory mediators, which is also useful in treating and improving inflammation.
도 1은 본 발명에 따른 신규한 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) 균주의 계통도이다(Raphagen B-0001: 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001).
도 2는 자외선(UVB) 처리 시 본 발명에 따른 균주 처리 후 MTT 분석을 통하여 인간 각질형성세포(HaCaT)의 세포 생존률을 측정한 그래프이다. (No. 1: 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001)
도 3은 자외선(UVB) 처리 시 인간 각질형성세포(HaCaT)의 콜라겐분해효소(MMP(Matrix metalloproteinase-1)) 발현율을 측정한 그래프이다. (No. 1: 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001)
도 4는 Raw 264.7 세포에서 본 발명에 따른 균주 처리 후 LPS 처리에 의한IL-1β 활성화 정도를 ELISA 분석법을 통해 확인한 그래프이다. (N: Control, LPS: LPS 처리군, 1: 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001, 처리군)1 is a schematic diagram of a novel Bacillus amyloliquefaciens strain according to the present invention (Raphagen B-0001: Bacillus amyloliquefaciens RPG-B0001).
Figure 2 is a graph measuring the cell survival rate of human keratinocytes (HaCaT) through MTT analysis after treatment with strain according to the present invention when UVB (UVB) treatment. (No. 1: Bacillus amyloliquefaciens RPG-B0001)
3 is a graph measuring the expression rate of collagenase (MMP (Matrix metalloproteinase-1)) of human keratinocytes (HaCaT) upon ultraviolet (UVB) treatment. (No. 1: Bacillus amyloliquefaciens RPG-B0001)
Figure 4 is a graph confirming the degree of IL-1β activation by LPS treatment after the strain treatment according to the present invention in Raw 264.7 cells by ELISA assay. (N: Control, LPS: LPS treatment group, 1: Bacillus amyloliquefaciens RPG-B0001, treatment group)
다른 식으로 정의되지 않는 한, 본 명세서에서 사용된 모든 기술적 및 과학적 용어들은 본 발명이 속하는 기술분야에서 숙련된 전문가에 의해서 통상적으로 이해되는 것과 동일한 의미를 갖는다. 일반적으로, 본 명세서에서 사용된 명명법은 본 기술분야에서 잘 알려져 있고 통상적으로 사용되는 것이다.Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is well known and commonly used in the art.
본 발명의 상세한 설명 등에서 사용되는 주요 용어의 정의는 다음과 같다.Definitions of main terms used in the detailed description of the present invention are as follows.
본 발명에서의 용어 "파쇄물"이란 균주를 detergent 등을 이용한 화학적 방법 또는 물리적 방법 등으로 파쇄하여 얻은 세포 용해물을 의미하며, 균주의 "배양액"이란 균주를 배양시킨 다음, 균주를 제외하고 남은 세포 배양용액을 의미한다. 추가적으로 본 발명에서 "배양물"이란 배양액 및/또는 배양된 균주를 포함하는 물질이다. As used herein, the term "crushed material" refers to a cell lysate obtained by crushing a strain by a chemical method or a physical method using a detergent or the like, and the "culture medium" of the strain is followed by culturing the strain and remaining cells except the strain. Means a culture solution. Additionally, in the present invention, a "culture" is a substance including a culture solution and / or a cultured strain.
이하, 구체적으로 본 발명을 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 일 관점에서, 신규한 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) 균주에 관한 것이다. 본 발명의 신규한 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) 균주는 지렁이 분변토에서 분리한 유산균이다. In one aspect, the present invention relates to a novel Bacillus amyloliquefaciens strain. The novel Bacillus amyloliquefaciens strain of the present invention is lactic acid bacteria isolated from earthworm feces.
본 발명에 따른 신규한 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) 균주는 서열번호 1의 16S rRNA 서열을 가지는 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) 균주임을 특징으로 한다. 한국미생물 보존센터(KFCC)에 미생물 분석을 의뢰한 결과, 본 발명에 따른 신규한 바실러스 아밀로리퀘파시엔스 균주는 서열번호 1 의 16S rRNA 서열 단편을 가지는 신규 균주로서 도 1과 같이 계통상 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) FN597644 균주와 가장 근접하게 나타나 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) 종으로 분류할 수는 있으나, 이와 64%의 homology를 보일 뿐인바 새로운 균주임을 확인할 수 있었다. 아울러, 분리된 신규 균주는 배양 온도 등 균주 특성이나 효능 면에서도 기존 균주와 상이한 효과를 보임을 확인하였다. Novel Bacillus amyl Lowry Quebec Pacific Enschede (Bacillus amyloliquefaciens) strain according to the invention is characterized in that the Bacillus amyl Lowry Quebec Pacific Enschede (Bacillus amyloliquefaciens) strain having a 16S rRNA sequence of SEQ ID NO: 1. As a result of requesting microbial analysis to the Korea Microorganism Conservation Center (KFCC), the novel Bacillus amyloliquefaciens strain according to the present invention is a novel strain having a 16S rRNA sequence fragment of SEQ ID NO: 1 as shown in FIG. The bacterium Bacillus amyloliquefaciens (Bcillus amyloliquefaciens ) was found to be closest to the FN597644 strain, but it could be classified as Bacillus amyloliquefaciens (Baccillus amyloliquefaciens ), but it showed a new strain as it showed only 64% homology. In addition, the isolated new strains showed different effects from the existing strains in terms of strain characteristics such as culture temperature and efficacy.
이에 본 발명자는 분리된 신규한 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) 균주를 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001이라 명명하고, 한국미생물보존센터 (Korean Culture Center of Microorganisms)에 2018년 01월 02일자로 기탁하였다(국제특허기탁번호 : KCCM12191P). 이에 본 발명은 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 (기탁번호 : KCCM12191P) 균주 1종을 제공한다. Accordingly, the inventor named the isolated Bacillus amyloliquefaciens strain Bacillus amyloliquefaciens RPG-B0001, and the 2018 Korean Culture Center of Microorganisms It was deposited on January 02, 2008 (International Patent Accession Number: KCCM12191P). Thus, the present invention provides one strain of Bacillus amyloliquefaciens ( Bacillus amyloliquefaciens ) RPG-B0001 (Accession No .: KCCM12191P).
본 발명의 일 실시예에서는, 본 발명에 따른 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주가 피부 노화 방지 및 주름 개선 효과를 가짐을 확인하였다. 먼저, 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주가 자외선으로부터 피부세포를 보호하여 피부의 노화를 방지할 수 있는지 확인하기 위하여, UVB를 처리 시 인간 각질형성세포주의 생존률을 측정하였다. 그 결과, 본 발명에 따른 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주 시료를 처리한 실험군에서 자외선 처리에도 불구하고 높은 생존율을 확인할 수 있었으며 이에 본 발명의 균주가 피부 노화 방지 효과가 있음을 확인할 수 있었다. 추가적으로, 피부주름을 생성시키는 콜라겐 분해효소(MMP(Matrix metalloproteinase-1)) 억제 여부를 테스트한 결과, 본 발명의 시료를 처리하지 않은 대조군의 경우 자외선 처리에 의하여 MMP(Matrix metalloproteinase-1) 발현이 3배 이상 현저히 증가함에 반하여, 본 발명에 따른 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주를 처리한 시험군에서는 자외선 비처리군(Control)과 거의 유사한 콜라겐 분해효소(MMP(Matrix metalloproteinase-1)) 발현을 나타내었다. 즉, 본 발명에 따른 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주가 피부노화방지 및 주름개선용 조성물로서 매우 유용한 것으로 확인되었다. In one embodiment of the present invention, Bacillus amyloliquefaciens ( Bacillus amyloliquefaciens ) RPG-B0001 strain according to the present invention was confirmed to have an anti-aging and wrinkle improvement effect. First, in order to check whether Bacillus amyloliquefaciens RPG-B0001 strain can prevent skin aging by protecting skin cells from ultraviolet rays, the survival rate of human keratinocytes was measured upon UVB treatment. As a result, the experimental group treated with Bacillus amyloliquefaciens RPG-B0001 strain sample according to the present invention was able to confirm a high survival rate despite the UV treatment, and thus the strain of the present invention has an anti-aging effect Could confirm. In addition, as a result of testing whether the collagen degrading enzyme (MMP (Matrix metalloproteinase-1)) that produces skin wrinkles was tested, in the case of the control group which did not process the sample of the present invention, MMP (Matrix metalloproteinase-1) expression was suppressed by UV treatment. In contrast, the test group treated with the Bacillus amyloliquefaciens RPG-B0001 strain according to the present invention increased significantly by more than three times. -1)) expression. That is, Bacillus amyloliquefaciens RPG-B0001 strain according to the present invention was found to be very useful as a composition for preventing skin aging and improving wrinkles.
따라서, 본 발명은 다른 관점에서, 본 발명에 따른 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주 및 그 파쇄물 및 그 배양물 중 어느 하나 이상을 포함하는 피부 노화 방지 또는 주름 개선용 화장료 조성물에 대한 것이다. 이때, 본 발명에 따른 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주 및 그 파쇄물이나 배양물은 피부 노화 방지 또는 주름 억제용 약학 조성물의 형태나 피부 노화 방지 또는 주름 개선용 건강기능식품의 형태로도 제공될 수 있다. Therefore, in another aspect, the present invention, Bacillus amyloliquefaciens ( Bacillus amyloliquefaciens ) RPG-B0001 strain and its lysate and cosmetic composition for anti-aging or wrinkle improvement comprising any one or more of the cultures thereof It is about. At this time, Bacillus amyloliquefaciens RPG-B0001 strain and its lysate or culture thereof according to the present invention is in the form of a pharmaceutical composition for preventing skin aging or anti-wrinkle or anti-aging skin aging or wrinkle improvement of health functional foods It may also be provided in the form.
본 발명의 다른 실시예에서는, 본 발명에 따른 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주가 항염증 활성을 가짐을 확인하였다. 즉, 염증반응에 관여하는 다양한 mediator 중 가장 중요한 factor가 염증성 cytokine인데, 염증유발모델에서 본 발명에 따른 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주가 유의하게 염증성 사이토카인인 IL-1β의 발현을 감소시킴을 알 수 있었다. 따라서, 본 발명은 또 다른 관점에서, 본 발명에 따른 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 포함하는 염증 치료용 약학 조성물에 대한 것이다. 이때, 염증은 피부 염증을 포함할 수 있다. In another embodiment of the present invention, Bacillus amyloliquefaciens ( Bacillus amyloliquefaciens ) RPG-B0001 strain according to the present invention was confirmed to have anti-inflammatory activity. In other words, the most important factor among the various mediators involved in the inflammatory response is inflammatory cytokine. In the inflammation-induced model, Bacillus amyloliquefaciens RPG-B0001 strain according to the present invention is IL-1β, which is a significantly inflammatory cytokine. It can be seen that decreases the expression of. Therefore, in another aspect, the present invention relates to a pharmaceutical composition for treating inflammation comprising at least one of Bacillus amyloliquefaciens RPG-B0001 strain, a lysate thereof and a culture thereof according to the present invention. . In this case, the inflammation may include skin inflammation.
이때, 본 발명에 따른 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주 및 그 파쇄물이나 배양물은 염증의 예방 또는 개선용 건강기능식품의 형태나 화장료 조성물의 형태로도 제공될 수 있다. At this time, Bacillus amyloliquefaciens ( Bacillus amyloliquefaciens ) RPG-B0001 strain according to the present invention and its lysate or culture thereof may also be provided in the form of a health functional food or cosmetic composition for the prevention or improvement of inflammation.
먼저, 본 발명에 따른 화장료 조성물은 다음에 의하여 제공될 수 있다. First, the cosmetic composition according to the present invention may be provided by the following.
즉, 본 발명에 따르면, 상기 본 발명에 따른 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주 및 그 파쇄물이나 배양물은 화장료 조성물의 전체 중량에 대해서 0.0001 ~ 30.0 중량% 함유될 수 있으며, 더욱 바람직하게는, 상기 균주 등은 화장료 조성물의 전체 중량에 대해서 0.001 ~ 10 중량% 함유되는 것을 특징으로 한다. 상기 균주 등의 함량이 0.0001 중량% 미만인 경우에는 피부개선 효과가 나타나지 않으며, 30.0 중량% 를 초과하는 경우에는 함유량 증가에 대한 피부 개선 효과 증대 정도가 미미하며, 제형상의 안전 및 안정성에 문제가 있으며 경제적이지도 못하다.That is, according to the present invention, Bacillus amyloliquefaciens ( Bacillus amyloliquefaciens ) RPG-B0001 strain according to the present invention and its shreds or cultures may be contained 0.0001 ~ 30.0% by weight relative to the total weight of the cosmetic composition, More preferably, the strain is characterized in that it contains 0.001 to 10% by weight relative to the total weight of the cosmetic composition. If the content of the strain is less than 0.0001% by weight, the skin improvement effect does not appear, and when the content of the strain exceeds 30.0% by weight, the degree of improvement of the skin improvement effect on the content increase is insignificant, and there is a problem in the safety and stability of the formulation. It's not economical either.
본 발명의 화장료 조성물에 포함되는 성분은 상기 유효 성분 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다. 본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 팩, 마사지크림 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The components included in the cosmetic composition of the present invention may include components conventionally used in cosmetic compositions in addition to the active ingredient, such as conventional auxiliaries such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings, and Carrier. Cosmetic compositions of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations, packs, massage creams and sprays and the like, but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, nutrition lotion, nutrition cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다. 본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소르비탄의 지방산 에스테르가 있다. 본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다. 본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드파우더가 이용될 수 있고, 특히 스프레이인경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다. 본 발명의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be. When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butylglycol oil, glycerol aliphatic ester, polyethyleneglycol or sorbitan. When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, and microcrystals are used as carrier components. Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used. When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used, in particular, in the case of spray, additionally chlorofluorohydrocarbon, propane Propellant such as butane or dimethyl ether. When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide ether. Sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
본 발명의 화장료 조성물이 비누, 계면활성제 함유 클렌징 제형 또는 계면활성제 비함유 클렌징 제형일 경우, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 구체적인 예로서, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 함유 클렌징 제형은 클렌징 폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 겔이며, 이에 한정되는 것은 아니다.When the cosmetic composition of the present invention is a soap, a surfactant-containing cleansing formulation or a surfactant-free cleansing formulation, it may be wiped off, peeled off or washed with water after application to the skin. As a specific example, the soap is liquid soap, powdered soap, solid soap and oil soap, the surfactant-containing cleansing formulation is a cleansing foam, cleansing water, cleansing towel and cleansing pack, the surfactant-free cleansing formulation is a cleansing cream , Cleansing lotion, cleansing water and cleansing gel, but are not limited thereto.
한편, 본 발명의 화장 방법은 본 발명의 화장료 조성물을 이용하는 모든 화장 방법을 일컫는다. 즉, 화장료 조성물을 이용하는 당업계에 공지된 모든 방법이 본 발명의 화장 방법에 속한다. 본 발명의 화장료 조성물은 단독 또는 중복하여 사용하거나, 본 발명 이외의 다른 화장료 조성물과 중복하여 사용할 수 있다. 또한 본 발명에 따른 화장료 조성물은 통상적인 사용방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.On the other hand, the makeup method of the present invention refers to all makeup methods using the cosmetic composition of the present invention. That is, all the methods known in the art using the cosmetic composition belong to the makeup method of the present invention. The cosmetic composition of the present invention may be used alone or in duplicate, or may be used in combination with other cosmetic compositions other than the present invention. In addition, the cosmetic composition according to the present invention may be used according to a conventional method of use, and the number of times of use may vary depending on the skin condition or taste of the user.
한편, 본 발명에 따른 약학 조성물은 다음에 의하여 제공될 수 있다. Meanwhile, the pharmaceutical composition according to the present invention may be provided by the following.
즉, 본 발명에 따른 균주, 그 파쇄물 및 그 배양물 중 어느 하나 이상을 유효성분으로 함유하는 약학 조성물은 이들을 각각 단독으로 포함하거나 하나 이상의 약학적으로 허용되는 담체, 부형제 또는 희석제를 포함하여 약학 조성물로 제공될 수 있으며, 상기 균주 등은 질환 및 이의 중증정도, 환자의 연령, 체중, 건강상태, 성별, 투여 경로 및 치료 기간 등에 따라 적절한 약학적으로 유효한 양으로 약학 조성물에 포함될 수 있다.In other words, the pharmaceutical composition containing any one or more of the strains, the lysates and the cultures thereof according to the present invention as an active ingredient, each alone or one or more pharmaceutically acceptable carriers, excipients or diluents The strain may be included in the pharmaceutical composition in an appropriate pharmaceutically effective amount according to the disease and its severity, age, weight, health status, sex, route of administration and duration of treatment.
상기에서 "약학적으로 허용되는"이란 생리학적으로 허용되고 인간에게 투여될 때, 통상적으로 위장 장애, 현기증과 같은 알레르기 반응 또는 이와 유사한 반응을 일으키지 않는 조성물을 말한다. 상기 담체, 부형제 및 희석제의 예로는, 락토즈, 덱스트로즈, 슈크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 폴리비닐피롤리톤, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.As used herein, "pharmaceutically acceptable" refers to a composition that is physiologically acceptable and does not cause an allergic reaction, such as gastrointestinal disorders, dizziness, or the like, when administered to a human. Examples of such carriers, excipients and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
상기 약학 조성물은 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제 및 방부제 등을 추가로 포함할 수 있다. 또한 본 발명의 약학 조성물은 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 공지된 방법을 사용하여 제형화될 수 있다. 제형은 분말, 과립, 정제, 에멀젼, 시럽, 에어로졸, 연질 또는 경질 젤라틴 캅셀, 멸균 주사 용액, 멸균 분말의 형태일 수 있다.The pharmaceutical composition may further include fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers and preservatives. Pharmaceutical compositions of the invention can also be formulated using methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal. The formulations may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders.
아울러, 본원에서 '기능성 식품'이란, 일반 식품에 본 발명에 따른 균주 또는 그 파쇄물 및 그 배양물 중 어느 하나 이상을 첨가함으로써 식품의 기능성을 향상시킨 것을 의미한다.In addition, the term "functional food" in the present application means that the functionality of the food is improved by adding any one or more of the strain according to the present invention or its lysate and its culture to the general food.
본 발명의 기능성 식품은 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 기능성 식품은, 예를 들어, 각종 식품류, 캔디, 초콜릿, 음료, 껌, 차, 비타민 복합제, 건강 보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.Functional food of the present invention can be used in a variety of drugs, food and beverages. The functional food of the present invention includes various foods, candy, chocolate, beverages, gums, teas, vitamin complexes, dietary supplements, and the like, and can be used in the form of powders, granules, tablets, capsules or beverages.
이때, 식품 또는 음료 중의 상기 균주 등의 양은 일반적으로 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ml를 기준으로 0.02 내지 10 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. At this time, the amount of the strain or the like in the food or beverage may generally be added in 0.01 to 15% by weight of the total food weight, the health beverage composition is 0.02 to 10 g, preferably 0.3 to 1 g based on 100 ml Can be added.
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 균주 등을 함유하는 것 외에 액체 성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 화합물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health beverage composition of the present invention contains the above strains as essential ingredients in the ratios indicated, and there are no particular limitations on the liquid components, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. . Examples of the above-mentioned natural carbohydrates are conventional monosaccharides such as disaccharides such as glucose and fructose, such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like. Sugars and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia compounds (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages and the like. The compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
실시예Example
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.
신규한 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주의 분리 및 시료의 준비Isolation of New Bacillus amyloliquefaciens RPG-B0001 Strains and Preparation of Samples
1-1: 신규한 바실러스 아밀로리퀘파시엔스(1-1: New Bacillus amyloliquefaciens ( Bacillus amyloliquefaciensBacillus amyloliquefaciens ) RPG-B0001 균주의 분리Isolation of RPG-B0001 Strains
10년된 된장에서 다수개의 균주 분리 후 선별과정을 거쳐 새로운 균주 RPG-B0001을 분리하였다. 이는 한국미생물 보존센터(KFCC)에 미생물 분석을 의뢰한 결과, 서열번호 1의 16S rRNA 서열을 가지는 신규 균주로서 도 1과 같이 계통상 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) FN597644 균주와 가장 근접하게 나타났다. 이에 이에 본 발명자는 분리된 신규한 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) 균주를 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001라 명명하였다. 그러나, 신규 분리된 균주는 가장 근접하게 나타난 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) FN597644 균주와도 64%의 homology를 보일 뿐인바 새로운 균주임을 확인할 수 있었다. A new strain, RPG-B0001, was isolated after several strains were isolated from 10-year-old doenjang. As a result of requesting microbial analysis to the Korea Microorganism Conservation Center (KFCC), it is a new strain having the 16S rRNA sequence of SEQ ID NO: 1, which is the closest to the strain Bacillus amyloliquefaciens FN597644 as shown in FIG. appear. Accordingly, the inventor named the isolated Bacillus amyloliquefaciens strain Bacillus amyloliquefaciens RPG-B0001. However, the newly isolated strain showed only 64% homology with the nearest Bacillus amyloliquefaciens FN597644 strain, which was confirmed to be a new strain.
분리된 신규 균주는 다음의 표 1과 같은 특성을 보였다. The isolated new strain showed the characteristics shown in Table 1 below.
본 발명에서 분리된 신규 균주는 특히 일반적인 바실러스 속 균주들이 24~30℃에서 배양되는 것과 달리, 고온에서 배양되는 특성을 보였다. 즉, 31 내지 45도에서, 바람직하게는 36℃ 정도에서 생육되는 고온성 특성을 보였다. 이외에도 발효 진행, 맛, 미생물 군집 형태에서도 상이한 모습을 나타내었다. The novel strain isolated from the present invention showed a characteristic of being cultured at a high temperature, unlike the general strains of the genus Bacillus is cultured at 24 ~ 30 ℃. That is, the thermophilic properties were grown at 31 to 45 degrees, preferably at about 36 ℃. In addition, the fermentation progress, taste, microbial community form was also different.
이에 본 발명자는 분리된 신규한 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주를 한국미생물보존센터 (Korean Culture Center of Microorganisms)에 2017년 11월 1일자로 기탁하였다(기탁번호:KCCM12191P ). Therefore, the present inventors deposited the isolated novel Bacillus amyloliquefaciens RPG-B0001 strain to the Korean Culture Center of Microorganisms on November 1, 2017 (Accession No .: KCCM12191P). .
1-2: 바실러스 아밀로리퀘파시엔스(1-2: Bacillus amyloliquefaciens ( Bacillus amyloliquefaciensBacillus amyloliquefaciens ) RPG-B0001 균주 시료의 준비) Preparation of RPG-B0001 Strain Sample
실시예 1-1에서 분리된 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주의 효능을 추가적으로 테스트하기 위하여 다음과 같이 시료를 준비하였다. In order to further test the efficacy of Bacillus amyloliquefaciens RPG-B0001 strain isolated in Example 1-1, a sample was prepared as follows.
즉, MRS broth(BD, USA)에서 분리된 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주를 24시간 배양한 다음 121℃에서 15분간 열처리한 후 냉각하여 사균화한 뒤, 1.0×105 ~1.0×106 cells/ml로 희석하여 시료를 준비하였다.That is, Bacillus amyloliquefaciens RPG-B0001 strain isolated from MRS broth (BD, USA) was incubated for 24 hours, then heat-treated at 121 ° C. for 15 minutes, cooled, and then sterilized, followed by 1.0 × 10. 5 ~ 1.0 × was prepared sample was diluted with 10 6 cells / ml.
신규한 바실러스 아밀로리퀘파시엔스(Bacillus amyloliquefaciens) RPG-B0001 균주의 피부 노화 방지 및 주름 개선 효능 확인Identification of Bacillus amyloliquefaciens RPG-B0001 Strain
2-1: 자외선에 대한 바실러스 아밀로리퀘파시엔스(2-1: Bacillus amyloliquefaciens against ultraviolet rays ( Bacillus amyloliquefaciensBacillus amyloliquefaciens ) RPG-B0001 균주의 인간 각질형성세포주 보호 효과Protective effect of RPG-B0001 strain on human keratinocytes
본 발명에 따른 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주가 자외선으로부터 인간 피부세포를 보호할 수 있는지 확인하기 위하여, 다음의 실험을 수행하였다. In order to check whether the Bacillus amyloliquefaciens RPG-B0001 strain according to the present invention can protect human skin cells from ultraviolet rays, the following experiment was performed.
먼저, 인간 각질형성세포주(HaCaT: CLS, Germany)는 10% 우혈청을 포함한 DMEM 배지(Dulbecco's modified Eagle's medium, Gibco 1210-0038)에서 배양하였고, 배양은 모두 37℃, 5% CO2 배양기에서 수행하였다.First, the human keratinocyte line (HaCaT: CLS, Germany) was incubated in DMEM medium (Dulbecco's modified Eagle's medium, Gibco 1210-0038) containing 10% bovine serum, and the cultures were all performed at 37 ° C., 5% CO 2 incubator. It was.
그 다음, 배양된 HaCaT 세포주를 트립신으로 처리하여 단일세포 현탁액을 만든 후, 6-well에 1×104 개씩 분주하여 24시간 배양하였다. 그런 다음, 우혈청이 포함되지 않은 DMEM 배지로 교환하여 다시 24시간 동안 배양한 후, 실시예 1의 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주 시료를 1×106 cells/well의 농도로 분주하여 24시간 배양하였다. 이후 인산완충용액(PBS)으로 세척하고, PBS를 넣은 상태에서 200mＪ/㎠농도의 UVB를 조사하였다. 시료를 처리하지 않은 세포들은 대조구로 동일하게 배양하였다.Then, the cultured HaCaT cell line was treated with trypsin to make a single cell suspension, and then cultured for 24 hours by dispensing 1 × 10 4 in 6-well. Then, the cells were exchanged with DMEM medium containing no bovine serum and cultured for another 24 hours, and then the Bacillus amyloliquefaciens RPG-B0001 strain sample of Example 1 was dispensed at a concentration of 1 × 10 6 cells / well. Incubated for 24 hours. After washing with phosphate buffer (PBS), the UVB of 200mＪ / ㎠ concentration in the state of PBS was irradiated. The cells not treated with the sample were cultured in the same manner as the control.
자외선 조사 24시간 후, 본 발명에 따른 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주 시료를 처리한 세포와 처리하지 않은 세포에 3-[4,5-디메틸티아졸-2-일]-2,5-디페닐테트라졸리움 브로마이드(MTT, Sigma) 용액을 넣고 37℃에서 4시간 동안 배양하였다. 이후 DMSO를 넣고 녹인 후 ELISA reader(Thermo Max, Molecular Devices Co.)를 이용하여 540㎚의 파장에서 형성된 포르마잔 다이의 광학적 농도(OD)을 측정하였다. 자외선을 조사하지 않은 세포의 OD값을 100%로 계산하여 상대적인 값을 세포의 생존수로 나타내었으며, 그 결과를 도 3에 나타내었다.After 24 hours of ultraviolet irradiation, 3- [4,5-dimethylthiazol-2-yl] -2,5 was treated to cells treated with and treated with Bacillus amyloliquefaciens RPG-B0001 strain samples according to the present invention. Diphenyltetrazolium bromide (MTT, Sigma) solution was added and incubated at 37 ° C. for 4 hours. After dissolving DMSO, the optical concentration (OD) of the formazan die formed at a wavelength of 540 nm was measured using an ELISA reader (Thermo Max, Molecular Devices Co.). The OD value of the cells not irradiated with UV was calculated as 100%, and the relative value was expressed as the survival number of the cells, and the results are shown in FIG. 3.
그 결과, 도 2 나타난 바와 같이, 시료를 처리하지 않은 대조군(도 2의 UVB)의 경우 자외선(UVB) 처리에 의하여 인간 각질형성세포주가 자외선 비처리군에 비하여 세포 생존도가 50% 이하로 떨어짐에 반하여, 본 발명에 따른 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주를 처리한 시험군(도 2의 No. 1)에서는 시료 비처리군보다 현저히 높은 생존도를 보였으며 특히 자외선 비처리군과 비교하여서도 이의 90% 이상의 생존도를 보였다. 이는 본 발명에 따른 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주가 자외선에 대한 높은 피부세포 보호 효과가 있음을 나타낸다. As a result, as shown in FIG. 2, in the control group (UVB of FIG. 2) not treated with the sample, human keratinocyte line was reduced to 50% or less by virtue of UVB treatment as compared to the non-UV treatment group. In contrast, the test group treated with the Bacillus amyloliquefaciens RPG-B0001 strain according to the present invention (No. 1 of FIG. 2) showed a significantly higher survival than the sample untreated group, especially compared with the UV untreated group. Even more than 90% of the survival was shown. This indicates that the Bacillus amyloliquefaciens RPG-B0001 strain according to the present invention has a high skin cell protective effect against ultraviolet rays.
2-2: 자외선 조사에 의하여 유도되는 콜라겐분해효소(Matrix metalloproteinase-1, MMP(Matrix metalloproteinase-1)) 생성 억제효과 확인2-2: Confirmation of the inhibitory effect of the production of collagenase (Matrix metalloproteinase-1, MMP (Matrix metalloproteinase-1)) induced by UV irradiation
자외선 노출에 의하여 MMP가 증가되는 경우, 증가된 MMPs는 피부의 콜라겐을 분해하여 피부주름을 형성시키는바, 자외선에 의해 증가된 MMP(Matrix metalloproteinase-1) 발현이 본 발명에 따른 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주에 의해 억제되는 효과를 확인하기 위하여 다음의 실험을 수행하였다.When MMP is increased by UV exposure, the increased MMPs break down collagen of the skin to form skin wrinkles. The expression of MMP (Matrix metalloproteinase-1) increased by UV light is according to the present invention. In order to confirm the effect inhibited by the Enns RPG-B0001 strain was carried out the following experiment.
먼저 실시예 2-1의 HaCaT 세포를 실시예 2-1과 동일한 방법으로 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주 시료를 처리하고 UVB를 조사하였다. 그 다음, 배양한 배지를 수거하여 MMP(Matrix metalloproteinase-1) 발현량 측정은 머크(MERCK)사의 QIA55 MMP(Matrix metalloproteinase-1) ELISA Kit 장비를 사용하여 수행하였다.First, the HaCaT cells of Example 2-1 were treated with a Bacillus amyloliquefaciens RPG-B0001 strain sample in the same manner as in Example 2-1, and irradiated with UVB. Then, the culture medium was collected and measurement of MMP (Matrix metalloproteinase-1) expression was measured using a Merck (QIA55) Matrix metalloproteinase-1 (MMP) ELISA Kit.
그 결과, 도 3에 나타난 바와 같이, 시료를 처리하지 않은 대조군(도 4의 UVB)의 경우 자외선(UVB) 처리에 의하여 인간 각질형성세포주에서 자외선 비처리군에 비하여 콜라겐 분해효소(MMP(Matrix metalloproteinase-1)) 발현이 3배 이상 현저히 증가함에 반하여, 본 발명에 따른 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주를 처리한 시험군(도 3의 No. 1)에서는 자외선 비처리군(Control)과 거의 유사한 콜라겐 분해효소(MMP(Matrix metalloproteinase-1)) 발현을 나타내었다. As a result, as shown in FIG. 3, the control group (UVB of FIG. 4), which was not treated with the sample, was treated with collagen-degrading enzyme (MMP (Matrix metalloproteinase) in human keratinocytes by UVB treatment. -1)) While the expression was significantly increased by more than three times, in the test group treated with Bacillus amyloliquefaciens RPG-B0001 strain according to the present invention (No. 1 in Fig. 3) Almost similar collagen degrading enzyme (MMP (Matrix metalloproteinase-1)) expression was shown.
즉, 본 발명에 따른 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주가 우수한 MMP(Matrix metalloproteinase-1) 발현 억제능을 보이는 것으로 피부노화방지 및 주름개선용 조성물로서 매우 유용한 것으로 확인되었다. That is, it was confirmed that the Bacillus amyloliquefaciens RPG-B0001 strain according to the present invention exhibits excellent suppression of Matrix metalloproteinase-1 (MMP) expression and is very useful as an anti-aging and antiwrinkle composition.
신규한 바실러스 아밀로리퀘파시엔스(New Bacillus amyloliquefaciens Bacillus amyloliquefaciensBacillus amyloliquefaciens ) RPG-B0001 균주의 항염증 효능 확인) Confirmation of anti-inflammatory efficacy of RPG-B0001 strain
3-1: LPS의 RAW 264.7 macrophage cell line 처리에 따른 염증성 cytokine 발현에 대한 바실러스 아밀로리퀘파시엔스(3-1: Bacillus amyloliquefaciens for inflammatory cytokine expression following LPS RAW 264.7 macrophage cell line treatment Bacillus amyloliquefaciensBacillus amyloliquefaciens ) RPG-B0001 시료의 저해 효과Inhibitory Effect of RPG-B0001 Sample
리포폴리사카라이드(LPS)를 macrophage cell에 처리하면 염증반응에 관여하는 다양한 mediator가 생산되는데, 가장 중요한 factor가 염증성 cytokine의 생산이다. 이에 가장 중요한 염증성 cytokine인 IL-1β의 LPS 자극에 의한 생산이 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주 시료의 처리에 의하여 저해되는지 확인하였다.Treatment of lipopolysaccharide (LPS) in macrophage cells produces a variety of mediators involved in the inflammatory response, the most important of which is the production of inflammatory cytokine. It was confirmed that LPS stimulation of IL-1β, the most important inflammatory cytokine, was inhibited by the treatment of Bacillus amyloliquefaciens RPG-B0001 strain samples.
바실러스 아밀로리퀘파시엔스 RPG-B0001 균주 시료의 LPS (Sigma, St Louis, MO)로 활성화된 사이토카인의 분비에 미치는 효과를 측정하기 위하여, 24-웰 플래이트에서 대식세포 RAW 264.7 (3×105 cells/well/1 ml)을 10％ FBS (fetal bovine serum) (Hyclone, Logan, Utah), 100 unit/ml 페니실린 (Thermo, Waltham, MA), 100 μg/ml 스트렙토마이신 (Thermo, Waltham, MA)가 포함된 RPMI 1640 배지 (Corning, Manassas, VA)를 이용하여 37℃, 5％ 이산화탄소의 환경에서 배양하였다. To determine the effect on the secretion of activated cytokines by LPS (Sigma, St Louis, MO) of Bacillus amyloliquefaciens RPG-B0001 strain samples, macrophage RAW 264.7 (3 × 10 5) in 24-well plates cells / well / 1 ml) with 10% FBS (fetal bovine serum) (Hyclone, Logan, Utah), 100 unit / ml penicillin (Thermo, Waltham, Mass.), 100 μg / ml streptomycin (Thermo, Waltham, Mass.) It was cultured in an environment of 37 ℃, 5% carbon dioxide using RPMI 1640 medium (Corning, Manassas, VA) containing.
그 다음, LPS (2 μg/ml)를 24시간 처리한 후, 실시예 1의 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주 시료를 1×105 cells/well의 농도로 처리하여 24시간 동안 배양한 다음, 이후 배양액을 배양액을 취하여 RAW264.7 세포에서 생성된 사이토카인 IL-1β의 양을 ELISA (enzyme-linked immunosorbent assay) 방법 (Elabscience, Bethesda, MD)으로 측정하였다.Then, after treating LPS (2 μg / ml) for 24 hours, the Bacillus amyloliquefaciens RPG-B0001 strain sample of Example 1 was incubated for 24 hours by treating at a concentration of 1 × 10 5 cells / well Subsequently, the culture medium was taken from the culture medium, and the amount of cytokine IL-1β produced in RAW264.7 cells was measured by an ELISA (enzyme-linked immunosorbent assay) method (Elabscience, Bethesda, MD).
그 결과, 도 4에 나타난 바와 같이, RAW 264.7 cell에 LPS 2μg /ml을 처리 후 실시예 2의 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주 시료를 첨가하여 배양한 후 배양액에 존재하는 IL-1β의 농도를 확인한 결과, LPS 만 처리한 군보다 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주 시료를 처리한 군(도 4의 No. 1)에서 IL-1β의 발현이 유의한 정도로 감소됨을 알 수 있었다.As a result, as shown in Figure 4, after treating LPS 2μg / ml to RAW 264.7 cells, the Bacillus amyloliquefaciens RPG-B0001 strain sample of Example 2 was added and cultured, and then the IL-1β present in the culture medium. As a result of confirming the concentration, it was found that the expression of IL-1β was significantly decreased in the group treated with the Bacillus amyloliquefaciens RPG-B0001 strain sample (No. 1 in FIG. 4) than the LPS-only group.
이러한 결과로 미루어 바실러스 아밀로리퀘파시엔스 RPG-B0001 균주 시료를 LPS로 자극된 RAW 264.7 macrophage cell을 이용한 in vitro 항염증 효과 실험 결과 매우 우수한 항염증 효과를 보유함을 알 수 있었다.These results suggest that the Bacillus amyloliquefaciens RPG-B0001 strain sample has an excellent anti-inflammatory effect in vitro using LPS-stimulated RAW 264.7 macrophage cells.
제조예 1. 약학제제 제조예Preparation Example 1 Pharmaceutical Preparation Example
제제예 1-1: 정제의 제조Formulation Example 1-1 Preparation of Tablets
실시예 1에서 제조된 균주 시료 100 ㎎을 옥수수 전분 100 ㎎, 유당 100 ㎎ 및 스테아린산 마그네슘 2㎎을 혼합하여 통상의 정제제조방법에 따라 제조하였다.100 mg of the strain sample prepared in Example 1 was prepared according to a conventional tablet preparation method by mixing 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate.
제제예 1-2: 캡슐제의 제조Formulation Example 1-2: Preparation of Capsule
실시예 1 또는 실시예 2에서 분리된 건조 균주 500 ㎎을 연질 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.500 mg of the dry strain isolated in Example 1 or Example 2 is filled into soft gelatin capsules to prepare capsules.
제제예 1-3: 시럽제의 제조Formulation Example 1-3: Preparation of Syrup
실시예 1 또는 실시예 2에서 분리한 균주 1 g, 이성화당 10 g, 만니톨 5 g, 적량의 정제수의 함량으로 통상적인 액제제의 제조방법에 따라 100 mL의 시럽제를 제조하였다.100 mL of syrup was prepared according to the conventional method of preparing a liquid formulation in the content of 1 g of the strain isolated from Example 1 or Example 2, 10 g of isomerized sugar, 5 g of mannitol, and an appropriate amount of purified water.
제제예 1-4: 주사제의 제조Formulation Example 1-4: Preparation of Injection
실시예 1 또는 실시예 2에서 분리한 균주 200 ㎎을 폴리옥시에틸렌 수소화 카스트로 오일을 함유하는 생리 식염수 200 ㎎에 가열 용해시켜 혼합 추출물을 0.1%의 농도로 함유하는 주사제를 제조하였다.200 mg of the strain isolated in Example 1 or Example 2 was dissolved by heating in 200 mg of physiological saline containing polyoxyethylene hydrogenated Castro oil to prepare an injection containing a mixed extract at a concentration of 0.1%.
제조예 2. 기능성 식품의 제조Preparation Example 2 Preparation of Functional Food
제조예 2-1: 기능성 음료의 제조Preparation Example 2-1 Preparation of Functional Drink
실시예 1 또는 실시예 2에서 분리한 균주 200㎎을 96㎖의 물에 용해시킨 후 보조제로서 비타민 C 500㎎, 교미제로서 구연산, 올리고당을 각각 1g 가하고, 보존재로서 나트륨벤조에이트 0.05g을 가한 후 정제수를 가하여 전량을 100㎖로 만들어 기능성 음료를 제조하였다.After dissolving 200 mg of the strain isolated in Example 1 or Example 2 in 96 ml of water, 500 mg of vitamin C as an adjuvant, 1 g of citric acid and oligosaccharides as a copulating agent were added, and 0.05 g of sodium benzoate was added as a preservative. After adding purified water to make a total amount of 100ml to prepare a functional beverage.
제조예 3. 화장품 제조예Preparation Example 3
제제예 1-1: 유연화장수(스킨로션)의 제조Formulation Example 1-1 Preparation of Soft Cosmetic Water (Skin Lotion)
다음 표의 조성을 갖는 유연화장수를 당업자의 통상적인 방법에 따라 제조하였다. Softening water having the composition shown in the following table was prepared according to conventional methods of those skilled in the art.
제제예 1-2: 팩의 제조Formulation Example 1-2: Preparation of Pack
다음 표의 조성을 갖는 팩을 당업자의 통상적인 방법에 따라 제조하였다. Packs having the compositions in the following table were prepared according to conventional methods of those skilled in the art.
이상으로 본 발명의 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.The specific parts of the present invention have been described in detail above, and for those skilled in the art, these specific descriptions are merely preferred embodiments, and the scope of the present invention is not limited thereto. Will be obvious. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
부호 없음Unsigned
<110> PARK, Byoung Hee <120> Bacillus amyloliquefaciens <130> PL18-046 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1428 <212> RNA <213> Bacillus amyloliquefaciens <400> 1 caagtcgagc ggacagatgg gagcttgctc cctgatgtta gcggcggacg ggtgagtaac 60 acgtgggtaa cctgcctgta agactgggat aactccggga aaccggggct aataccggat 120 gcttgtttga accgcatggt tcagacataa aaggtggctt cggctaccac ttacagatgg 180 acccgcggcg cattagctag ttggtgaggt aacggctcac caaggcgacg atgcgtagcc 240 gacctgagag ggtgatcggc cacactggga ctgagacacg gcccagactc ctacgggagg 300 cagcagtagg gaatcttccg caatggacga aagtctgacg gagcaacgcc gcgtgagtga 360 tgaaggtttt cggatcgtaa agctctgttg ttagggaaga acaagtgccg ttcaaatagg 420 gcggcacctt gacggtacct aaccagaaag ccacggctaa ctacgtgcca gcagccgcgg 480 taatacgtag gtggcaagcg ttgtccggaa ttattgggcg taaagggctc gcaggcggtt 540 tcttaagtct gatgtgaaag cccccggctc aaccggggag ggtcattgga aactggggaa 600 cttgagtgca gaagaggaga gtggaattcc acgtgtagcg gtgaaatgcg tagagatgtg 660 gaggaacacc agtggcgaag gcgactctct ggtctgtaac tgacgctgag gagcgaaagc 720 gtggggagcg aacaggatta gataccctgg tagtccacgc cgtaaacgat gagtgctaag 780 tgttaggggg tttccgcccc ttagtgctgc agctaacgca ttaagcactc cgcctgggga 840 gtacggtcgc aagactgaaa ctcaaaggaa ttgacggggg cccgcacaag cggtggagca 900 tgtggtttaa ttcgaagcaa cgcgaagaac cttaccaggt cttgacatcc tctgacaatc 960 ctagagatag gacgtcccct tcgggggcag agtgacaggt ggtgcatggt tgtcgtcagc 1020 tcgtgtcgtg agatgttggg ttaagtcccg caacgagcgc aacccttgat cttagttgcc 1080 agcattcagt tgggcactct aaggtgactg ccggtgacaa accggaggaa ggtggggatg 1140 acgtcaaatc atcatgcccc ttatgacctg ggctacacac gtgctacaat gggcagaaca 1200 aagggcagcg aaaccgcgag gttaagccaa tcccacaaat ctgttctcag ttcggatcgc 1260 agtctgcaac tcgactgcgt gaagctggaa tcgctagtaa tcgcggatca gcatgccgcg 1320 gtgaatacgt tcccgggcct tgtacacacc gcccgtcaca ccacgagagt ttgtaacacc 1380 cgaagtcggt gaggtaacct tttaggagcc agccgccgaa ggtggacg 1428 <110> PARK, Byoung Hee <120> Bacillus amyloliquefaciens <130> PL18-046 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1428 <212> RNA <213> Bacillus amyloliquefaciens <400> 1 caagtcgagc ggacagatgg gagcttgctc cctgatgtta gcggcggacg ggtgagtaac 60 acgtgggtaa cctgcctgta agactgggat aactccggga aaccggggct aataccggat 120 gcttgtttga accgcatggt tcagacataa aaggtggctt cggctaccac ttacagatgg 180 acccgcggcg cattagctag ttggtgaggt aacggctcac caaggcgacg atgcgtagcc 240 gacctgagag ggtgatcggc cacactggga ctgagacacg gcccagactc ctacgggagg 300 cagcagtagg gaatcttccg caatggacga aagtctgacg gagcaacgcc gcgtgagtga 360 tgaaggtttt cggatcgtaa agctctgttg ttagggaaga acaagtgccg ttcaaatagg 420 gcggcacctt gacggtacct aaccagaaag ccacggctaa ctacgtgcca gcagccgcgg 480 taatacgtag gtggcaagcg ttgtccggaa ttattgggcg taaagggctc gcaggcggtt 540 tcttaagtct gatgtgaaag cccccggctc aaccggggag ggtcattgga aactggggaa 600 cttgagtgca gaagaggaga gtggaattcc acgtgtagcg gtgaaatgcg tagagatgtg 660 gaggaacacc agtggcgaag gcgactctct ggtctgtaac tgacgctgag gagcgaaagc 720 gtggggagcg aacaggatta gataccctgg tagtccacgc cgtaaacgat gagtgctaag 780 tgttaggggg tttccgcccc ttagtgctgc agctaacgca ttaagcactc cgcctgggga 840 gtacggtcgc aagactgaaa ctcaaaggaa ttgacggggg cccgcacaag cggtggagca 900 tgtggtttaa ttcgaagcaa cgcgaagaac cttaccaggt cttgacatcc tctgacaatc 960 ctagagatag gacgtcccct tcgggggcag agtgacaggt ggtgcatggt tgtcgtcagc 1020 tcgtgtcgtg agatgttggg ttaagtcccg caacgagcgc aacccttgat cttagttgcc 1080 agcattcagt tgggcactct aaggtgactg ccggtgacaa accggaggaa ggtggggatg 1140 acgtcaaatc atcatgcccc ttatgacctg ggctacacac gtgctacaat gggcagaaca 1200 aagggcagcg aaaccgcgag gttaagccaa tcccacaaat ctgttctcag ttcggatcgc 1260 agtctgcaac tcgactgcgt gaagctggaa tcgctagtaa tcgcggatca gcatgccgcg 1320 gtgaatacgt tcccgggcct tgtacacacc gcccgtcaca ccacgagagt ttgtaacacc 1380 cgaagtcggt gaggtaacct tttaggagcc agccgccgaa ggtggacg 1428
Claims (4)
A cosmetic composition for protecting skin against ultraviolet rays, comprising any one or more of the strain of claim 1, its lysate, and its culture, and having an inhibitory ability to Matrix metalloproteinase-1 (MMP-1).
A health functional food for protecting skin against ultraviolet rays comprising any one or more of the strain of claim 1, its lysate, and its culture.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180089530A KR102055890B1 (en) | 2018-07-31 | 2018-07-31 | Novel Bacillus amyloliquefaciens and Use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180089530A KR102055890B1 (en) | 2018-07-31 | 2018-07-31 | Novel Bacillus amyloliquefaciens and Use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102055890B1 true KR102055890B1 (en) | 2020-01-22 |
Family
ID=69368395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180089530A KR102055890B1 (en) | 2018-07-31 | 2018-07-31 | Novel Bacillus amyloliquefaciens and Use thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102055890B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102317282B1 (en) * | 2021-04-30 | 2021-10-26 | 주식회사 바람인터내셔날 | Cosmetic Composition for Skin Barrier Enhancement and Skin Anti-inflammation Comprising Dahlia Pinnata Fermented Extract |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004508392A (en) * | 2000-09-13 | 2004-03-18 | ザ、プロクター、エンド、ギャンブル、カンパニー | Makeup method |
| KR100791609B1 (en) | 2006-11-10 | 2008-01-04 | 건국대학교 산학협력단 | Probiotic bacillus amyloliquefaciens ku801 with higher ability of immunity and its use |
| KR101773342B1 (en) | 2015-10-21 | 2017-09-01 | 대한민국 | Bacillus amyloliquefaciens DH1 having antifungal activity and its use |
-
2018
- 2018-07-31 KR KR1020180089530A patent/KR102055890B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004508392A (en) * | 2000-09-13 | 2004-03-18 | ザ、プロクター、エンド、ギャンブル、カンパニー | Makeup method |
| KR100791609B1 (en) | 2006-11-10 | 2008-01-04 | 건국대학교 산학협력단 | Probiotic bacillus amyloliquefaciens ku801 with higher ability of immunity and its use |
| KR101773342B1 (en) | 2015-10-21 | 2017-09-01 | 대한민국 | Bacillus amyloliquefaciens DH1 having antifungal activity and its use |
Non-Patent Citations (1)
| Title |
|---|
| Journal of the Korea Academia-Industrial cooperation Society, Vol.18, pp.534-544 (2017.) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102317282B1 (en) * | 2021-04-30 | 2021-10-26 | 주식회사 바람인터내셔날 | Cosmetic Composition for Skin Barrier Enhancement and Skin Anti-inflammation Comprising Dahlia Pinnata Fermented Extract |
| KR20220149395A (en) * | 2021-04-30 | 2022-11-08 | 주식회사 바람인터내셔날 | Cosmetic Composition for Skin Barrier Enhancement and Skin Anti-inflammation Comprising Dahlia Pinnata Fermented Extract |
| KR102623887B1 (en) | 2021-04-30 | 2024-01-12 | 주식회사 바람인터내셔날 | Cosmetic Composition for Skin Barrier Enhancement and Skin Anti-inflammation Comprising Dahlia Pinnata Fermented Extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101492003B1 (en) | Probiotics of Lactobacillus plantarum HY7714 for skin wrinkle inhibitory and moisurizing effects and use of thereof as skin anti-wrinkle or moisturizing products | |
| KR102032033B1 (en) | Fermentation method of lactic acid bacteria using citrus fruit and its use | |
| KR20140128675A (en) | Probiotics of Lactobacillus gasseri HY7025 for skin wrinkle inhibitory and moisturizing effects and use of thereof as skin anti-wrinkle or moisturizing products | |
| KR20160110829A (en) | The milk fermented product using Lactobacillus paracasei HY7301 for skin whitening and products containing thereof as effective component | |
| KR101876669B1 (en) | Novel Pichia kudriavzevii and Use thereof | |
| KR20190079514A (en) | Cosmetic composition for skin moisturizing comprising fermented aloe as effective component | |
| KR101917497B1 (en) | Novel Lactobacillus buchneri and Use thereof | |
| KR101409764B1 (en) | Comprising lactic acid fermentation product of Gelidium amansil extract as an Active Ingredient for Improving Skin Wrinkle | |
| KR101800961B1 (en) | Skin-lightening Composition Using an Extract of Reed or a Product Obtained by Fermenting the Same with Lactic Acid Bacteria | |
| KR101409760B1 (en) | Comprising lactic acid fermentation product of Cirsium japonicum and Gelidium amansil extract as an Active Ingredient for Improving Skin Wrinkle | |
| KR101889647B1 (en) | Novel Lactobacillus Harbinensis and Use thereof | |
| KR101876668B1 (en) | Novel Saccharomycopsis fibuligera and Use thereof | |
| EP2123290A1 (en) | Melanogenesis inhibitory composition | |
| KR102055890B1 (en) | Novel Bacillus amyloliquefaciens and Use thereof | |
| KR102404383B1 (en) | Cosmetic composition for skin anti-aging or anti-wrinkle containing Weissella cibaria cell lysates | |
| KR102055895B1 (en) | Novel Bacillus licheniformis and Use thereof | |
| KR102238329B1 (en) | Skin funtional composition containing fermented natural product complex by lactic acid | |
| KR102055892B1 (en) | Novel Bacillus methylotrophicus and Use thereof | |
| KR102014312B1 (en) | Skin-whitening functional composition including polyopes affinis extracts | |
| KR20200068575A (en) | Cosmetic composition for anti-wrinkle and whitening comprising Lilium longiflorum extract and Allium hookeri extract as active ingredients | |
| KR102453568B1 (en) | Composition for moisturizing and anti-inflammation comprising fermented Codium fragile extract fermented by inoculating Bacillus safensis strain | |
| KR102370528B1 (en) | Compositions containing Beta vulgaris fermentation extract | |
| KR101897485B1 (en) | Composition for improving skin whitening and wrinkle comprising gallic acid glycoside as effective component | |
| KR102302072B1 (en) | Method for producing fermented Beta vulgaris extract with improved antioxidant activity and fermented Beta vulgaris extract produced by the same method | |
| KR102670653B1 (en) | Composition for improving hair loss containing fermented product of lactic acid bacteria of Helianthus tuberosus extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GRNT | Written decision to grant |